Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation
Adrian G. Sacher(Princess Margaret Cancer Centre), Jayesh Desai(Peter MacCallum Cancer Centre), Manish R. Patel(Sarah Cannon), Mark T. Lin(Princess Margaret Cancer Centre), Jong Seok Lee(Brigham and Women's Hospital), Erminia Massarelli(The University of Texas MD Anderson Cancer Center), Julie Chang(University of Wisconsin–Madison), Jennifer L. Schutzman(Cancer Research Institute), Neekesh V. Dharia(Broad Institute), Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Wilson H. Miller(Jewish General Hospital), Patricia LoRusso(Yale Cancer Center), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Sae‐Won Han(Seoul National University Hospital), Elena Garralda(Memorial Sloan Kettering Cancer Center), Stephanie Royer‐Joo(Princess Margaret Cancer Centre), Samantha Bowyer(Princess Margaret Cancer Centre), Martin Förster, Matthew Krebs(Christie's), Sandhya Mandlekar(University of Illinois Chicago), Armando Santoro(IRCCS Humanitas Research Hospital), Zhen Shi(Princess Margaret Cancer Centre), Yoonha Choi(Ewha Womans University), Tae Won Kim(Ulsan College), Michael L. Cheng(University of California, San Francisco), Alejandro Falcón(Princess Margaret Cancer Centre)
Cited by 307
Related Papers
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k